John Kiely is Director of Amneal Pharmaceuticals, Inc.. Currently has a direct ownership of 267,175 shares of AMRX, which is worth approximately $2.33 Million. The most recent transaction as insider was on Nov 22, 2024, when has been sold 17,058 shares (Class A Common Stock) at a price of $8.38 per share, resulting in proceeds of $142,946. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 267K
4.48% 3M change
49.03% 12M change
Total Value Held $2.33 Million

John Kiely Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 22 2024
SELL
Open market or private sale
$142,946 $8.38 p/Share
17,058 Reduced 6.0%
267,175 Class A Common Stock
Nov 22 2024
BUY
Exercise of conversion of derivative security
$135,688 $4.76 p/Share
28,506 Added 9.11%
284,233 Class A Common Stock
May 10 2024
BUY
Exercise of conversion of derivative security
-
76,453 Added 23.02%
255,727 Class A Common Stock
May 10 2023
BUY
Exercise of conversion of derivative security
-
80,128 Added 30.89%
179,274 Class A Common Stock
May 08 2022
BUY
Exercise of conversion of derivative security
-
35,406 Added 26.31%
99,146 Class A Common Stock
May 06 2021
BUY
Exercise of conversion of derivative security
-
46,218 Added 42.03%
63,740 Class A Common Stock
Dec 15 2020
BUY
Exercise of conversion of derivative security
-
7,522 Added 30.04%
17,522 Class A Common Stock

Also insider at

ZVO
Zovio Inc Consumer Defensive
JK

John Kiely

Director
Chandler, AZ

Track Institutional and Insider Activities on AMRX

Follow Amneal Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMRX shares.

Notify only if
Any

Insider Trading

Get notified when an Amneal Pharmaceuticals, Inc. insider buys or sells AMRX shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Amneal Pharmaceuticals, Inc.

Track Activities on AMRX